摘要
目的探讨普拉克索治疗帕金森患者的临床效果及安全性.方法选取2015年3月至2016年8月我院收治的帕金森患者共118例作为研究对象,随机分为对照组和观察组,每组59例.对照组患者采用美多芭治疗,观察组患者采用普拉克索治疗,观察和比较两组患者临床疗效、生活质量评分和不良反应发生率.结果和对照组相比,观察组的临床疗效、生活质量评分均更优,差异具有统计学意义（P〈0.05）;两组的不良反应发生率比较,差异无统计学意义（P〉0.05）.结论在帕金森疾病的治疗过程中,普拉克索能够使患者获得更佳疗效,并提高其生活质量,用药安全可靠,值得推广应用.
Objective To explore the therapeutic effect and safety of pramipexole in the treatment of Parkinson＇s disease patients. Methods From March 2015 to June 2016, 118 cases of Parkinson＇s disease patients enrolled in our hospital were selected as the research objects and randomly divided into control group and observation group, with 59 cases in each group. The patients in control group were treated with metoprolol, while the patients in observation group were given pramipexole for treatment. The clinical efficacy, quality of life score and the incidence rate of adverse reactions were observed and compared between the two groups. Results Compared with the control group, the total effective rate and quality of life score of the observation group were better, the differences were statistically significant （P〈0.05）; the incidence rate of adverse reactions of the observation group was lower than that of the control group, there was no significant difference （P〉0.05）. Conclusion In the course of Parkinson＇s disease treatment, pramipexole can improve the efficacy and the quality of life with security and reliability for patients, which is worthy of popularization and application.
出处
《临床研究》
2017年第4期64-65,共2页
Clinical Research
关键词
帕金森
普拉克索
安全性评价
Parkinson＇s disease
pramipexole
safty evaluation
